Vyleesi Shortage Update: What Patients Need to Know in 2026

If you've been searching for a Vyleesi shortage update for 2026, here is the short answer: Vyleesi (bremelanotide) is not currently on the FDA's official drug shortage list. Cosette Pharmaceuticals has not reported any manufacturing disruptions, and supply is not an issue in the traditional sense.

But that doesn't mean Vyleesi is easy to get. Patients across the US continue to struggle with what amounts to a structural access problem — not a supply shortage. This post explains exactly what's happening and what you can do about it.

Is Vyleesi in a Shortage in 2026?

No. As of 2026, Vyleesi is not on the FDA drug shortage database. There are no public reports of manufacturing problems, ingredient shortages, or distribution facility failures affecting Cosette Pharmaceuticals.

However, Vyleesi has structural access challenges that function like a shortage for many patients:

• Specialty pharmacy-only distribution: Vyleesi cannot be filled at standard retail pharmacies. Prescriptions must go through an approved specialty pharmacy network.
• Insurance prior authorization: Many plans require extensive documentation and PA review before approving Vyleesi coverage.
• High cash cost: At approximately $290 per autoinjector without assistance, cost creates a de facto access barrier for uninsured and underinsured patients.
• Limited prescribing volume: HSDD remains underdiagnosed, and many providers are unfamiliar with Vyleesi or uncomfortable prescribing it.

A Brief History of Vyleesi's Availability

Vyleesi was FDA-approved on June 21, 2019, making it the second medication approved for HSDD in premenopausal women (after Addyi in 2015). It was originally marketed by AMAG Pharmaceuticals and later acquired by Cosette Pharmaceuticals.

Since its launch, Vyleesi has been a specialty pharmacy-only medication. This distribution model has remained unchanged. No generic version is expected until at least 2033 based on current patent protection.

What's Happening With Insurance Coverage in 2026?

Coverage for Vyleesi varies significantly by insurance plan. Some commercial plans cover it, often with prior authorization required. Medicare coverage is limited. Medicaid and TRICARE typically do not cover Vyleesi.

For commercially insured patients facing high out-of-pocket costs, Cosette's BlinkRx Copay Assistance program can reduce costs to as little as $0. However, patients on government insurance programs don't qualify for this assistance, making cost an ongoing barrier.

Will There Be a Generic Vyleesi?

Not anytime soon. Drug patent analysis by DrugPatentWatch suggests the earliest possible generic entry for Vyleesi (bremelanotide autoinjector) is around November 2033. Until then, patients will continue to rely on the brand-name product and its specialty pharmacy distribution model.

What Can Patients Do Right Now?

Here are the most effective steps for patients dealing with Vyleesi access challenges in 2026:

1. Verify your prescription routing. Make sure your doctor sent the prescription to a Vyleesi-approved specialty pharmacy, not a retail chain.
2. Check PA status. If your insurance requires prior authorization, confirm your provider has submitted it and follow up on the status.
3. Apply for the BlinkRx Copay Assistance program. Call 1-833-799-5028 or visit vyleesi.com/getting-started if you have commercial insurance.
4. Use medfinder to find specialty pharmacies near you that can fill the prescription.
5. Ask about alternatives. If access is taking too long, speak with your provider about Addyi (flibanserin) or other options while you wait.

The Bottom Line

Vyleesi is not in a formal shortage in 2026, but access challenges are real and persistent. The combination of specialty pharmacy-only distribution, insurance barriers, and high cash costs makes it harder to obtain than most medications. If you're struggling, use our guide to finding Vyleesi in stock and don't hesitate to loop in your provider about your options.